Spots Global Cancer Trial Database for metastatic uveal melanoma
Every month we try and update this database with for metastatic uveal melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| FHD-286 in Subjects With Metastatic Uveal Melanoma | NCT04879017 | Metastatic Uvea... | FHD-286 | 18 Years - | Foghorn Therapeutics Inc. | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | NCT01328106 | GNA11 Mutation-... GNAQ Mutation-p... Cancer Metastatic Uvea... | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | NCT06121180 | Metastatic Uvea... | ZIV-Aflibercept Cemiplimab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | NCT03865212 | Clinical Stage ... Clinical Stage ... Metastatic Chor... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Me... | Recombinant Ves... | 18 Years - | Mayo Clinic | |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | NCT05987332 | Metastatic Uvea... | IDE196 Crizotinib Pembrolizumab Ipilimumab Nivolumab Dacarbazine | 18 Years - | IDEAYA Biosciences | |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | NCT03025256 | Acral Lentigino... Central Nervous... Clinical Stage ... Leptomeningeal ... Melanocytoma Metastatic Lung... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Lumbar Puncture Magnetic Resona... Nivolumab Positron Emissi... | 18 Years - | M.D. Anderson Cancer Center | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye | NCT02697630 | Metastatic Uvea... | Pembrolizumab Entinostat | 18 Years - | Vastra Gotaland Region | |
| Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases | NCT04812470 | Metastatic Uvea... Metastatic Cuta... | Autologous Tumo... Melphalan Interleukin-2 | 18 Years - | Vastra Gotaland Region | |
| Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma | NCT01438658 | Uveal Melanoma | - | Hadassah Medical Organization | ||
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals | |
| Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | NCT05075993 | Metastatic Esop... Gastric Cancer Metastatic Head... Metastatic Hepa... Metastatic HPV ... Metastatic Ovar... Metastatic Soft... Metastatic Uvea... | LVGN3616 + LVGN... LVGN3616 + LVGN... LVGN3616 + LVGN... LVGN3616 + LVGN... | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | NCT01585194 | Metastatic Uvea... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | NCT05677373 | Advanced Uveal ... Metastatic Uvea... Unresectable Uv... | BRD4 Inhibitor ... Trametinib Computed Tomogr... Magnetic Resona... Biospecimen col... Biospecimen col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of SEA-CD40 Given With Other Drugs in Cancers | NCT04993677 | Melanoma Carcinoma, Non-... | SEA-CD40 pembrolizumab pemetrexed carboplatin | 18 Years - | Seagen Inc. | |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | NCT06121180 | Metastatic Uvea... | ZIV-Aflibercept Cemiplimab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | NCT05677373 | Advanced Uveal ... Metastatic Uvea... Unresectable Uv... | BRD4 Inhibitor ... Trametinib Computed Tomogr... Magnetic Resona... Biospecimen col... Biospecimen col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | NCT01585194 | Metastatic Uvea... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | NCT04552223 | Metastatic Uvea... | Nivolumab Relatlimab | 18 Years - | University of Miami | |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | NCT06121180 | Metastatic Uvea... | ZIV-Aflibercept Cemiplimab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) | NCT04118062 | Metastatic Uvea... Triple Negative... Luminal B Breas... Pediatric Cance... | Questionnaires Semi-structured... Focus Group DELPHI Consensu... | 18 Years - | Institut Curie | |
| A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | NCT02601378 | Uveal Melanoma | LXS196 LXS196 and HDM2... | 18 Years - | Novartis | |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | NCT03947385 | Metastatic Uvea... Cutaneous Melan... Colorectal Canc... Other Solid Tum... | IDE196 Binimetinib Crizotinib | 18 Years - | IDEAYA Biosciences | |
| A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma | NCT01551459 | Metastatic Uvea... | Dacarbazine Sunitinib | 18 Years - | The Clatterbridge Cancer Centre NHS Foundation Trust | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases | NCT04812470 | Metastatic Uvea... Metastatic Cuta... | Autologous Tumo... Melphalan Interleukin-2 | 18 Years - | Vastra Gotaland Region | |
| Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | NCT01328106 | GNA11 Mutation-... GNAQ Mutation-p... Cancer Metastatic Uvea... | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
